Deepika Tikoo Md, Gupta Meenakshi Md.
Denosumab: a new treatment option for osteoporosis.
Professional Med J Jan ;19(2):141-4.

Osteoporosis is the most common metabolic bone disease in developed countries. One of its major problems is the long term morbidity and poor quality of life of patients. Receptor activator of nuclear factor-kB, its ligand and osteoprotegrin pathway plays an important role in bone remodeling. Receptor activator of nuclear factor-kB interacts with receptor activator of nuclear factor-kB ligand leading to activation of osteoclasts. Denosumab, a fully monoclonal antibody to receptor activator of nuclear factor-kB ligand prevents its binding to receptor activator of nuclear factor-kB and can effectively suppress the bone loss in osteoporosis. Various clinical studies have shown that Denosumab has good efficacy in decreasing bone resorption and has a favourable safety profile also.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com